Cardium gets access to new polymer-based NO technology
The new polymer-based technology represents a practical way to integrate the use of NO into a variety of wound healing products, which could include granulated and powder dressings,
Amberstone Biosciences has signed a partnership and licence agreement with Shanghai Henlius Biotech for conditionally activated T-cell engager candidates to treat solid tumours.
Under the contract, HKPI-JV is expected to support the bio pharmaceutical companies to commercialise therapies in Egypt by recruiting, training and placing pharmaceutical sales representatives; forming and managing